FORM 3
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935
or Section 30(f) of the Investment Company Act of 1940
1. Name and Address of Reporting Person
Novartis AG
Schwarzwaldallee 215
CH-4002 Basel, Switzerland
2. Date of Event Requiring Statement (Month/Day/Year)
11/09/98
3. IRS or Social Security Number of Reporting Person (Voluntary)
4. Issuer Name and Ticker or Trading Symbol
Trega Biosciences, Inc. ("TRGA")
5. Relationship of Reporting Person to Issuer
(Check all applicable)
Director X 10% Owner
--- ---
Officer (give title below) Other (specify below)
--- ---
-----------------------------
6. If Amendment, Date of Original (Month/Day/Year)
7. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
---
X Form filed by More than One Reporting Person
---
Table I - Non-Derivative Securities Beneficially Owned
<TABLE>
<CAPTION>
1. Title of Security 2. Amount of Securities 3. Ownership 4. Nature of Indirect Beneficial Ownership
(Instr.4) Beneficially Owned Form: Direct (Instr. 5)
(Instr. 4) (D) or Indirect
<S> <C> <C> <C>
Common Stock 1,866,667 I I(1)
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
5(b)(v).
- -------------
(1) The shares are held by Novartis Pharma AG, a wholly owned subsidiary
of Novartis AG.
(over)
<PAGE>
Form 3 (continued)
TABLE II--Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
<TABLE>
<CAPTION>
1. Title of 2. Date 3. Title and Amount of 4. Conver- 5. Owner- 6. Nature of Indirect
Derivative Security Exercisable Securities Underlying sion or ship Beneficial Ownership
(Instr. 4) and Expira- Derivative Security Exercise Form of (Instr. 5)
tion Date (Instr. 4) Price of Deriva-
(Month/Day/ Deri- tive
Year) vative Security:
Security Direct
(D) or
Date Expira- Title Amount Indirect
Exer- tion or (I)
cisable Date Number (Instr. 5)
of
Shares
<S> <C> <C> <C> <C> <C> <C> <C>
</TABLE>
Explanation of Responses:
** Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
NOVARTIS AG
/s/ Anita Buchli
- ---------------------------------- ---------------------
**Signature of Reporting Person Date
/s/ Christoph Mader
- ---------------------------------- ---------------------
**Signature of Reporting Person Date
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficent, See Instruction 6 for procedure.
<PAGE>
Joint Filer Information
Name: Novartis Pharma AG
Address: Lichtstrasse 35
CH-4002 Basel
Switzerland
Designated Filer: Novartis AG
Issuer and Ticker
Symbol: Trega Biosciences, Inc. ("TRGA")
Signature: NOVARTIS PHARMA AG
By: /s/ Martin Henrich
-----------------------------------
Name: Martin Henrich
Title: Senior Corporate Counsel
By: /s/ Christoph Mader
-----------------------------------
Name: Christoph Mader
Title: Senior Corporate Counsel
